11C-Acetate Tracers in Metastatic Prostate Cancer Patients with Rising PSA
| Author and year | n | Tracer | Clinical state | Study | Purpose and endpoint | Statistical method | Conclusion |
|---|---|---|---|---|---|---|---|
| Sandblom et al. (63), 2006 | 20 | 11C-acetate | Rising PSA | Prospective | Purpose: disease detection (local, nodal, metastatic) | None | Pathologic uptake, 75% |
| Endpoints: | |||||||
| Lesions assessed with CIM | |||||||
| Histopathology | |||||||
| Wachter et al. (71), 2006 | 50 | 11C-acetate | Rising PSA | Prospective | Purpose: disease detection (local, nodal, metastatic) with retrospective CT/MRI fusion | None | Treatment influence, 28% (14/50) |
| Endpoint: lesions assessed with CIM-histopathology | |||||||
| Albrecht et al. (62), 2007 | 32 | 11C-acetate | Rising PSA | Prospective | Purpose: disease detection (local, nodal, metastatic) using early and late PET | Intercategory variation κ-test | RT group: 5/6 PET + biopsy-proven |
| Endpoints: | RP group: 3/8 PET+ responding to RT | ||||||
| Histopathology | |||||||
| Decrease in PSA after irradiation to primary site | |||||||
| Lesions assessed with CIM |
CIM = conventional imaging modality; RT = radiotherapy; RP = radical prostatectomy.